Skip to main content
Top
Published in: Current Rheumatology Reports 11/2018

Open Access 01-11-2018 | Infection and Arthritis (K Winthrop, Section Editor)

Differentiating Disease Flare From Infection: A Common Problem in Rheumatology. Do 18F-FDG PET/CT Scans and Novel Biomarkers Hold The Answer?

Authors: Elizabeth Mabey, Andrew Rutherford, James Galloway

Published in: Current Rheumatology Reports | Issue 11/2018

Login to get access

Abstract

Purpose of review

Fever is common within rheumatology but it is often challenging to identify its source. To do so correctly is paramount in patients with an underlying inflammatory condition receiving immunosuppressive therapy. This review article looks at the available evidence and merits of both 18F-fluoro-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scans and new proposed biomarkers in determining the cause of fever within rheumatology.

Recent findings

18F-FDG PET/CT scans are already an established tool in the detection and diagnosis of malignancy and are emerging for use in fever of unknown origin. More recently, they have been used to identify rheumatological causes of fever such as large vessel vasculitis and adult-onset Still’s disease. Within these conditions, biomarkers such as procalcitonin and presepsin may help to differentiate endogenous from exogenous pyrogens.

Summary

18F-FDG PET/CT scanning shows promise in locating the source of pyrogens and may be superior to other conventional forms of imaging. As evidence and test availability increases, its use is likely to become commonplace in the diagnostic work-up of fever. Once a source is located, selected biomarkers may be used to confirm a cause.
Literature
1.
go back to reference Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine. 1961;40:1–30.CrossRef Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine. 1961;40:1–30.CrossRef
2.
go back to reference Durack DT, Street AC. Fever of unknown origin – reexamined and redefined. Curr Clin Top Infect Dis. 1991;11:35–51.PubMed Durack DT, Street AC. Fever of unknown origin – reexamined and redefined. Curr Clin Top Infect Dis. 1991;11:35–51.PubMed
3.
go back to reference Bleeker-Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multi-centre study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine. 2007;86:26–38.CrossRef Bleeker-Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multi-centre study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine. 2007;86:26–38.CrossRef
4.
go back to reference Schönau V, Vogel K, Englbrecht M, et al. The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. Ann Rheum Dis. 2018;77:70–7.CrossRef Schönau V, Vogel K, Englbrecht M, et al. The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study. Ann Rheum Dis. 2018;77:70–7.CrossRef
5.
go back to reference Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin N Am. 2001;39(5):883–917.CrossRef Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin N Am. 2001;39(5):883–917.CrossRef
6.
go back to reference Kouijzer IJ, Bleeker-Rovers CP, Oyen WJ. FDG-PET in fever of unknown origin. Semin Nucl Med. 2013;43:333–9.CrossRef Kouijzer IJ, Bleeker-Rovers CP, Oyen WJ. FDG-PET in fever of unknown origin. Semin Nucl Med. 2013;43:333–9.CrossRef
7.
go back to reference Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis. 2001;1(5):326–33.CrossRef Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis. 2001;1(5):326–33.CrossRef
8.
go back to reference • Bharucha T, Rutherford A, Skeoch S, et al. Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis and dephi exercise. Clin Radiol. 2017. Available from: 10.1016/j.crad.2017.04.014 [Accessed 22nd January 2018]. This systematic review evaluates available evidence for the use of FDG-PET/CT in fever of unknown origin and discusses cost vs. benefits. • Bharucha T, Rutherford A, Skeoch S, et al. Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis and dephi exercise. Clin Radiol. 2017. Available from: 10.1016/j.crad.2017.04.014 [Accessed 22nd January 2018]. This systematic review evaluates available evidence for the use of FDG-PET/CT in fever of unknown origin and discusses cost vs. benefits.
9.
go back to reference • Imfeld S, Rottenburger C, Schegk E, et al. [18F] FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis – lessons from a vasculitis clinic. Eur Heart J Cardiovasc Imaging. 2017. This article evaluates the value of FDG-PET/CT in giant cell arteritis and discusses where false positive results may be obtained. • Imfeld S, Rottenburger C, Schegk E, et al. [18F] FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis – lessons from a vasculitis clinic. Eur Heart J Cardiovasc Imaging. 2017. This article evaluates the value of FDG-PET/CT in giant cell arteritis and discusses where false positive results may be obtained.
10.
go back to reference Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48(1):35–45.PubMed Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48(1):35–45.PubMed
11.
go back to reference Clifford A, Burrell S, Hanly JG. Positron emission tomography/computed tomography for the diagnosis and assessment of giant cell arteritis: when to consider it and why. J Rheumatol. 2012;39:1909–11.CrossRef Clifford A, Burrell S, Hanly JG. Positron emission tomography/computed tomography for the diagnosis and assessment of giant cell arteritis: when to consider it and why. J Rheumatol. 2012;39:1909–11.CrossRef
12.
go back to reference Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatic and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis’. Br J Rheumatol. 1996;35:1161–8.CrossRef Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatic and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis’. Br J Rheumatol. 1996;35:1161–8.CrossRef
13.
go back to reference Hall S, Barr W, Lie JT, et al. Takayasu arteritis. A study of 32 North American patients. Medicine. 1985;64:89–99.CrossRef Hall S, Barr W, Lie JT, et al. Takayasu arteritis. A study of 32 North American patients. Medicine. 1985;64:89–99.CrossRef
14.
go back to reference Treglia G, Mattoli MV, Leccisotti L, et al. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol. 2011;30(10):1265–75.CrossRef Treglia G, Mattoli MV, Leccisotti L, et al. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol. 2011;30(10):1265–75.CrossRef
15.
go back to reference Ergül N, Cermik TF. FDG-PET or PET/CT in fever of unknown origin: the diagnostic role of underlying primary disease. Int J Mol Imaging. 2011;3:2011. Ergül N, Cermik TF. FDG-PET or PET/CT in fever of unknown origin: the diagnostic role of underlying primary disease. Int J Mol Imaging. 2011;3:2011.
16.
go back to reference Chong EW, Robertson AJ. Is temporal artery biopsy a worthwile procedure? ANZ J Surg. 2005;75(6):388–91.CrossRef Chong EW, Robertson AJ. Is temporal artery biopsy a worthwile procedure? ANZ J Surg. 2005;75(6):388–91.CrossRef
17.
go back to reference Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine. 2015;94(14):e622.CrossRef Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine. 2015;94(14):e622.CrossRef
18.
go back to reference • Grayson PC, Alehashemi S, Bagheri AA, et al. Positron emission tomography as an imaging biomarker in a prospective longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheum. 2017. https://doi.org/10.1002/art.40379 This study evaluates the use of FDG-PET/CT in patients with large vessel vasculitis as compared to patients with vasculitis mimics.CrossRef • Grayson PC, Alehashemi S, Bagheri AA, et al. Positron emission tomography as an imaging biomarker in a prospective longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheum. 2017. https://​doi.​org/​10.​1002/​art.​40379 This study evaluates the use of FDG-PET/CT in patients with large vessel vasculitis as compared to patients with vasculitis mimics.CrossRef
19.
go back to reference Glaudemans AW, de Vries EF, Galli F, et al. The use of F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013 Glaudemans AW, de Vries EF, Galli F, et al. The use of F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013
20.
go back to reference Galloway J, Cope AP. The ying and yang of fever in rheumatic disease. Clin Med. 2015;15(3):288–91.CrossRef Galloway J, Cope AP. The ying and yang of fever in rheumatic disease. Clin Med. 2015;15(3):288–91.CrossRef
21.
go back to reference Yamashita H, Kubota K, Takahashi Y, et al. Clinical value of 18F-fluoro-deoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still’s disease: a seven-case series and review of the literature. Mod Rheumatol. 2014;24(4):645–50.CrossRef Yamashita H, Kubota K, Takahashi Y, et al. Clinical value of 18F-fluoro-deoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still’s disease: a seven-case series and review of the literature. Mod Rheumatol. 2014;24(4):645–50.CrossRef
22.
go back to reference Dong MJ, Wang CQ, Zhao K, et al. 18F-FDG PET/CT in patients with adult-onset Still’s disease. Clin Rheumatol. 2015;34(12):2047–56.CrossRef Dong MJ, Wang CQ, Zhao K, et al. 18F-FDG PET/CT in patients with adult-onset Still’s disease. Clin Rheumatol. 2015;34(12):2047–56.CrossRef
23.
go back to reference Firooz N, Albert DA, Wallace DJ, et al. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus. 2011;20:588–97.CrossRef Firooz N, Albert DA, Wallace DJ, et al. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus. 2011;20:588–97.CrossRef
24.
go back to reference Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:197.CrossRef Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:197.CrossRef
25.
go back to reference Shaikh MM, Hermans LE, van Laar JM. Is serum procalcitonin measurement a useful addition to a rheumatologist’s repertoire? A review of its diagnostic role in systemic inflammatory diseases and joint infections. Rheumatology. 2014;54(2):231–40.CrossRef Shaikh MM, Hermans LE, van Laar JM. Is serum procalcitonin measurement a useful addition to a rheumatologist’s repertoire? A review of its diagnostic role in systemic inflammatory diseases and joint infections. Rheumatology. 2014;54(2):231–40.CrossRef
26.
go back to reference Scire CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24:123–8.PubMed Scire CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24:123–8.PubMed
27.
go back to reference Shen CJ, Wu MS, Lin KH, et al. The use of procalcitonin in the diagnosis of bone and joint infections: a systemic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2013;32:807–14.CrossRef Shen CJ, Wu MS, Lin KH, et al. The use of procalcitonin in the diagnosis of bone and joint infections: a systemic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2013;32:807–14.CrossRef
28.
go back to reference Sato H, Tanabe N, Murasawa A, et al. Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol. 2012;39(8):1517–23.CrossRef Sato H, Tanabe N, Murasawa A, et al. Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol. 2012;39(8):1517–23.CrossRef
29.
go back to reference Kim HA, Jeon JY, An JM, et al. C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol. 2012;39(4):728–34.CrossRef Kim HA, Jeon JY, An JM, et al. C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol. 2012;39(4):728–34.CrossRef
30.
go back to reference Tamaki K, Kogata Y, Sugiyama D, et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol. 2008;35(1):114–9.PubMed Tamaki K, Kogata Y, Sugiyama D, et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol. 2008;35(1):114–9.PubMed
31.
go back to reference Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med. 2014;5:16–9.CrossRef Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med. 2014;5:16–9.CrossRef
32.
go back to reference Endo S, Suzuki Y, Takahashi G, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis; a multicenter prospective study. J Infect Chemother. 2014;20:30–4.CrossRef Endo S, Suzuki Y, Takahashi G, et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis; a multicenter prospective study. J Infect Chemother. 2014;20:30–4.CrossRef
33.
go back to reference • Tsujimoto K, Hata A, Fujita M, et al. Presepsin and procalcitonin as biomarkers of systemic bacterial infection in patients with rheumatoid arthritis. Int J Rheum Dis. 2016. This article compares the use of presepsin and procalcitonin in patients with rheumatoid arthritis and systemic infection. • Tsujimoto K, Hata A, Fujita M, et al. Presepsin and procalcitonin as biomarkers of systemic bacterial infection in patients with rheumatoid arthritis. Int J Rheum Dis. 2016. This article compares the use of presepsin and procalcitonin in patients with rheumatoid arthritis and systemic infection.
34.
go back to reference Tsuji S, Kitatoube A, Kikuchi-Taura A, et al. Elevated soluble CD14-subtype (PRESEPSIN; P-SEP) levels in rheumatoid arthritis (RA) patients with bacterial infection. Mod Rheumatol. 2017;27(4):718–20.CrossRef Tsuji S, Kitatoube A, Kikuchi-Taura A, et al. Elevated soluble CD14-subtype (PRESEPSIN; P-SEP) levels in rheumatoid arthritis (RA) patients with bacterial infection. Mod Rheumatol. 2017;27(4):718–20.CrossRef
35.
go back to reference • Ettinger M, Calliess T, Kielstein JT, et al. Circulating biomarkers for discrimination between aseptic joint failure, low-grade infection, and high-grade septic failure. Clin Infect Dis. 2015;61(3):332–41 This article compares different biomarkers in aseptic vs. septic joint pathology and concludes that combinations of biomarkers are superior to any one alone.CrossRef • Ettinger M, Calliess T, Kielstein JT, et al. Circulating biomarkers for discrimination between aseptic joint failure, low-grade infection, and high-grade septic failure. Clin Infect Dis. 2015;61(3):332–41 This article compares different biomarkers in aseptic vs. septic joint pathology and concludes that combinations of biomarkers are superior to any one alone.CrossRef
36.
go back to reference Buttaro MA, Tanoira I, Comba F, et al. Combining C-reactive protein and interleukin-6 may be useful to detect periprosthetic hip infection. Clin Orthop Relat Res. 2010;468:3263–7.CrossRef Buttaro MA, Tanoira I, Comba F, et al. Combining C-reactive protein and interleukin-6 may be useful to detect periprosthetic hip infection. Clin Orthop Relat Res. 2010;468:3263–7.CrossRef
Metadata
Title
Differentiating Disease Flare From Infection: A Common Problem in Rheumatology. Do 18F-FDG PET/CT Scans and Novel Biomarkers Hold The Answer?
Authors
Elizabeth Mabey
Andrew Rutherford
James Galloway
Publication date
01-11-2018
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 11/2018
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-018-0779-4

Other articles of this Issue 11/2018

Current Rheumatology Reports 11/2018 Go to the issue

Complementary and Alternative Medicine (S Kolasinski, Section Editor)

Natural Products for Promoting Joint Health and Managing Osteoarthritis

Orphan Diseases (Bernhard Manger, Section Editor)

Hypophosphatasia: From Diagnosis to Treatment

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.